MedTrace Logo

Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease

NCT00186667 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-04-09

No results posted yet for this study

Summary

Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.

Conditions

  • Graft vs Host Disease
  • Blood and Marrow Transplant (BMT)

Interventions

PROCEDURE

high dose chemotherapy and autologous hematopoietic cell transplant

Sponsors & Collaborators

Principal Investigators

  • Laura Johnston · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-31
Primary Completion
2000-01-31
Completion
2005-09-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186667 on ClinicalTrials.gov